Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Hyperphosphatemia is a frecuent and clinically significant complication in peritoneal dialysis (PD), associated with mineral bone disorders and increased cardiovascular risk. It is more prevalent in individuals on automated peritoneal dialysis (APD) than on continuous ambulatory peritoneal dialysis (CAPD). Tidal peritoneal dialysis (TPD) may offer a theoretical advantage in the management of hyperphosphatemia; however, its application in this context remains largely underexplored.
A quasi-experimental, pre-post study was conducted at a single center between March and August 2025. 44 APD patients were transitioned to TPD for 6 weeks. Serum phosphorus (primary outcome), PTH, calcium, hemoglobin, BUN, creatinine, and ultrafiltration were analyzed. Statistical analysis was performed using paired or independent t tests and Wilcoxon tests as appropriate.
The mean age was 47.2 ± 15.8 years, 59% being female, mean duration on PD was 46.8 ± 35.2 months. Phosphorus levels were significantly reduced from 6.16 ± 1.44 to 5.35 ± 0.94 mg/dL (p < 0.001) following TPD. A phosphorus reduction was obsered in 81.8% of patients, with 40.9% achieving a decrease ≥1.0 mg/dL. A more profound effect was observed in patients with hyperphosphatemia (>5.5mg/dL), experiencing a mean reduction of -1.20 mg/dL, compared to those without hyperphosphatemia that remained relatively stable, with a slight increase of +0.23 mg/dL (p < 0.05. PTH levels also decreased significantly from 344.0 ± 221.3 to 312.2 ± 211.5 pg/mL (p<0.05), other parameters remained unchanged. TPD modality was well tolerated by all patients
Variable
Basal (Mean±SD o Median [IC])
Tidal (Mean±SD o Median [IC])
p value
Phosphorus (mg/dL)
6.16 ± 1.44
5.35 ± 0.94
< 0.001
PTH (pg/ml)
344.02 ± 221.34
312.20 ± 211.47
< 0.05
Calcium (mg/dL)
9.24 (8.50-10.00)
9.38 (8.85-9.70)
0.476
Hemoglobin (g/dL)
10.05 (9.00-11.93)
10.10 (9.10-11.95)
0.375
BUN (mg/dL)
58.99 ± 12.16
59.63 ± 11.89
0.740
Creatinine (mg/dL)
13.41 ± 3.88
13.27 ± 3.69
0.595
Total ultrafiltration (ml)
914.00 (458.75-1231.75)
928.00 (476.25-1314.25)
0.561
Albumin (mg/dL)
3.96 ± 0.48
3.89 ± 0.44
0.286
Potassium (mg/dL)
4.60 (4.25-5.00)
4.71 (4.11-5.12)
0.578
Phosphorus intake (mg in 24 horas)
1240.78 ± 503.64
1209.09 ± 418.33
0.606
Total Volume (L)
9.35 (7.55-11.57)
9.60 (7.47-11.85)
0.172
TPD is often recommended for patients who experience discomfort or prolonged drainage times, this study highlighs additional potential clinical benefits. The effect was more pronounced in patients with baseline hyperphosphatemia supporting TPD as a viable adjunctive strategy in the management of hyperhphosatemia in APD
